NBTX Nanobiotix S.A.
USHealthcareAs of 2026-07-10 16:00
Why NBTX matters now
Nanobiotix S.A. (NBTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $40.07 with +2.88% on the session and $2.03B in market capitalization; recent performance reads 1-month -21.49% and YTD +56.88%.
The latest financial table shown here is Q4 2025, with revenue of $3.0M, net income of $-18.6M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.2%.
The latest indexable market news headline is "Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-17.02
P/S
51.95
EV/EBITDA
-131.12
DCF Value
$-3.78
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-36.5%
Net Margin
-80.8%
ROE
31.2%
ROA
-35.4%
ROIC
-74.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.0M | $-18.6M | $-0.39 |
| FY 2025 | $29.6M | $-24.0M | $-0.50 |
| Q2 2025 | $26.6M | $-5.4M | $-0.11 |
| Q4 2024 | $-16.5M | $-46.3M | $-0.98 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$38.00
Target (Median)
$38.00
Target Range
$30.00 - $46.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
FR
Exchange
—
Beta
0.59
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.